Multiple motor regions of the brain are underactive during lower limb movements in Parkinson's patients, according to a study.

Published Date: 26 Apr 2023

Parkinson's disease is a prevalent neurodegenerative condition that impairs movement. A person's gait and balance are eventually affected by the disease, which frequently starts with minor hand tremors.

Read Full News

Latest News

FDA Expands Indication for n‐Butyl Cyanoacrylate in Chronic Subdural Hematoma Isabella Ciccone, MPH

The expanded indication brings n-butyl cyanoacrylate’s established performance into the treatment of chronic subdural hematoma, a condition for which traditional surgical interventions may not always be suitable or effective.

Phase 3b STRENGTH Trial Provides Greater Support for Intrathecal SMA Gene Therapy Marco Meglio

Phase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.

NeuroVoices: Alireza Atri, MD, PhD, on Notable CTAD Trial Presentations, EVOKE Data Alireza Atri, MD, PhD, Isabella Ciccone, MPH

The director of the Banner Sun Health Research Institute discussed a variety of meaningful Alzheimer disease research presented at the 2024 Clinical Trials on Alzheimer's Disease Conference (CTAD).

What the First Intrathecal Gene Therapy Means for SMA Clinicians and Researchers Marco Meglio

Angela Lek, PhD, chief research officer of the Muscular Dystrophy Association, discusses the FDA approval of intrathecal onasemnogene abeparvovec (Itvisma; Novartis) and what it means for SMA treatment across older pediatric and adult populations.

Genetic Testing in Adult Epilepsy: GEAN’s Plan to Standardize Practice and Study Adult Outcomes Marco Meglio

Elizabeth Gerard, MD, an epileptologist at Northwestern Medicine, provided clinical insights on a new consortium, GEAN, which aims to expand genetic testing and define adult phenotypes for rare genetic epilepsies across North America.

A Clinical Review of the 2025 Restless Leg Syndrome Guidelines Louie Pasculli, Andy Berkowski, MD, PhD

Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.

Todays Updates

Frontlines with Frontera: Using Artificial Intelligence to Rethink Seizure Management in the Neuro ICU Jennifer Frontera, MD, Sahar Zafar, MD, MBBS

Frontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]

NeurologyLive® Friday 5 — December 19, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.

Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook Marco Meglio

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

Fear of Movement, Central Sensitization May Worsen Outcomes in Gout

Fear of Movement, Central Sensitization May Worsen Outcomes in Gout

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life

Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life

Todays Updates

Frontlines with Frontera: Using Artificial Intelligence to Rethink Seizure Management in the Neuro ICU Jennifer Frontera, MD, Sahar Zafar, MD, MBBS

Frontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]

NeurologyLive® Friday 5 — December 19, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.

Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook Marco Meglio

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

Fear of Movement, Central Sensitization May Worsen Outcomes in Gout

Fear of Movement, Central Sensitization May Worsen Outcomes in Gout

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life

Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life

Latest News

The expanded indication brings n-butyl cyanoacrylate’s established performance into the treatment of chronic subdural hematoma, a condition for which traditional surgical interventions may not always be suitable or effective.

Phase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.

The director of the Banner Sun Health Research Institute discussed a variety of meaningful Alzheimer disease research presented at the 2024 Clinical Trials on Alzheimer's Disease Conference (CTAD).

Angela Lek, PhD, chief research officer of the Muscular Dystrophy Association, discusses the FDA approval of intrathecal onasemnogene abeparvovec (Itvisma; Novartis) and what it means for SMA treatment across older pediatric and adult populations.

Elizabeth Gerard, MD, an epileptologist at Northwestern Medicine, provided clinical insights on a new consortium, GEAN, which aims to expand genetic testing and define adult phenotypes for rare genetic epilepsies across North America.

Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.

News All Time

Episode 156: Building Better Mood and Behavior Care for Parkinson Disease Marco Meglio, Sneha Mantri, MD, MS

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis Isabella Ciccone, MPH

Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.

FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS Isabella Ciccone, MPH

The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.

EPX-100 Shows Promising Seizure Reduction in Ongoing Open-Label Extension Louie Pasculli

New data from the open-label extension of Harmony Biosciences’ Phase 3 ARGUS trial show that EPX-100 (clemizole) achieved a median 50% reduction in countable motor seizures in patients with Dravet Syndrome.

Cell Therapy Deramiocel Meets Primary End Point in Phase 3 DMD Cardiomyopathy Trial Isabella Ciccone, MPH

Capricor Therapeutics anticipates that detailed phase 3 data from the HOPE-3 study will be submitted for presentation at a future scientific meeting and for publication in a peer-reviewed journal.

Michael Sperling, MD, on AES Lifetime Achievement Award, Evolution in Epilepsy Care Michael R. Sperling, MD, Louie Pasculli

Michael Sperling, MD, Baldwin Keyes Professor of Neurology at Vice Chair for Research at the Sidney Kimmel Medical College, spoke about the significance of receiving the Founders Award and the current state of epilepsy.

Z-Rostudirsen Meets Primary End Point in Phase 1/2 DELIVER Trial for Duchenne Muscular Dystrophy Isabella Ciccone, MPH

Long-term treatment with z-rostudirsen over 24 months showed sustained functional improvements across all end points in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

AES Poster Showcases Feasibility of Mobile App to Track Daily Self-Reporting Epilepsy Outcomes Isabella Ciccone, MPH

A new study presented at AES 2025 reported that a cognitive-behavioral intervention via mobile application for patients with epilepsy can reliably capture daily self-reported outcomes.

NeuroVoices: Richard Rammo, MD, on How Thalamic Neuromodulation is Evolving for Drug Resistant Epilepsy Marco Meglio, Richard Rammo, MD

The neurosurgeon at Cleveland Clinic discussed the goals of the AES thalamic neuromodulation special interest group and the major clinical and research priorities shaping the future of neuromodulation for drug resistant epilepsy.

FDA Accepts NDA for Low-Sodium Oxybate TRN-257 in Narcolepsy and Idiopathic Hypersomnia Isabella Ciccone, MPH

TRN-257, a treatment in development for adults with narcolepsy and idiopathic hypersomnia, is designed to reduce daily sodium exposure relative to existing higher-sodium therapies.

FDA Action Update, November 2025: Approvals, Clearance, and Boxed Warning Isabella Ciccone, MPH

Catch up on any of the neurology news headlines you may have missed in November 2025, compiled into 1 place by the NeurologyLive® team.

Long-Term Expanded Access Program Data Support Phase 3 Development of Bexicaserin in Developmental Epileptic Encephalopathies Marco Meglio

New findings reveal bexicaserin significantly reduces seizure frequency in patients with developmental and epileptic encephalopathies, supporting its advancement to phase 3 trials.

Survey identifies Fever-Related Seizure Reduction as Key Feature of CDKL5 Deficiency Disorder Louie Pasculli

A recent survey reveals fever significantly reduces seizure frequency in CDKL5 Deficiency Disorder, highlighting potential therapeutic strategies for patients.

Inside the 2026 MDA Conference: Keynote Insights and Evolving Neuromuscular Care Marco Meglio, Sharon Hesterlee, PhD

Sharon Hesterlee, PhD, President and CEO of the Muscular Dystrophy Association, discussed the 2026 MDA Conference, the significance of its keynote speaker, and the evolving therapeutic landscape in neuromuscular medicine.

PERC Analysis Highlights Factors Influencing Candidacy for Pediatric Drug-Resistant Epilepsy Surgery Isabella Ciccone, MPH

A new study presented at AES 2025 examined factors linked to declining surgery for pediatric drug-resistant epilepsy and highlighted variability in candidate selection across centers.

Stiripentol Reduces Seizure Burden in Patients with Lennox-Gastaut Syndrome, Study Shows Louie Pasculli

A new phase 2 study presented at AES 2025 showed that stiripentol may reduce seizure burden in patients with Lennox-Gastaut syndrome.

Recommended News For You

Could AI plus lasers help catch very early breast cancers?

Radiation therapy for patients with breast cancer

Novel Agent for Chronic GVHD Wins FDA Approval

Taking Charge of Your Cancer Journey.

Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.

Certain Oral Bacteria May Be a Risk Factor for Head and Neck Cancer

Increased Exercise May Lower the Risk of Prostate Cancer.

Recommended Articles For You

Beyond Symptoms: The Predictive Promise of Targeted Radionuclide Therapy in Palliative Oncology 

The Unseen Threat: Uncovering the Risks of Pancoast Tumor 

Feline Anemia: Diagnosis and Treatment with Focus on Rasburicase Complications 

Personalized Cancer Vaccines: The Next Frontier in Precision Oncology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI Model as Effective as Radiologists in Detecting Prostate Cancer on MRI

2.

Omitting Biopsy After Negative MRI Halves Diagnoses of Insignificant Prostate Cancer

3.

How to keep your prostate healthy and lower your risk of developing serious problems

4.

Highly Successful Treatment of Lynch Syndrome Patients with PD-1 Inhibitors for Colorectal Cancer.

5.

novel approach to test the toxicity of cancer drugs.

1.

Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies

2.

Personalized Neoantigen Vaccines and the Promise of a Less Toxic Future in Pediatric Oncology

3.

Unlocking the Potential of Elotuzumab: A Promising New Cancer Treatment

4.

Breaking Barriers: Innovative Approaches in Brain Tumor Treatment

5.

Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

2.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV

3.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

4.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective

5.

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot